Clinical Trial Update: The Effect of Rivaroxaban in Sickle Cell Disease [Phase 2]

View source ↗

Summary

Phase 2 clinical trial assessing rivaroxaban in sickle cell disease has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Beta0-thalassemia
• Sickle Cell Disease

Drugs mentioned

• Rivaroxaban (rivaroxaban)

Snippet

Sponsor: University of North Carolina, Chapel Hill | Conditions: Sickle Cell Anemia, Sickle Cell-Beta0-Thalassemia | Phase 2 | Status: COMPLETED | Results posted: 2020-04-13